Sensex
79,809.65 profit arw -270.92 (-0.34%)
Nifty
24,426.85 profit arw -74.05 (-0.30%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 18-Aug-2025
Hot Pursuit
18-Aug-2025     15:45

Marksans Pharma rises as UK subsidiary gets approval for Metformin Prolonged release tablets

The approval was granted by the UK regulatory authorities, allowing Relonchem to market the widely used anti-diabetic medication in three dosage strengths. Metformin is commonly prescribed for the treatment of type 2 diabetes and is considered a frontline therapy for managing blood glucose levels.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company's consolidated net profit dropped 34.3% to Rs 58.31 crore despite of 4.97% jump in revenue from operations to Rs 619.98 crore in Q1 FY26 over Q1 FY25.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

79,809.65 -270.92 (-0.34%)

Nifty

24,426.85 -74.05 (-0.30%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

25,077.63 78.80(0.32%)